잠시만 기다려 주세요. 로딩중입니다.

An overview of chondrosarcoma with a focus on nanoscale therapeutics

Journal of Pharmaceutical Investigation 2020년 50권 6호 p.537 ~ 552
김동현, 이한솔, 문용현, 고석진, 박준선, 이상민, Kang Nae-Won, Lee Mee-Yeon, 조정원, 김대덕, 이재영,
소속 상세정보
김동현 ( Kim Dong-Hyun ) - Chungnam National University College of Pharmacy
이한솔 ( Lee Han-Sol ) - Chungnam National University College of Pharmacy
문용현 ( Mun Yong-Hyeon ) - Chungnam National University College of Pharmacy
고석진 ( Koh Seok-Jin ) - Chungnam National University College of Pharmacy
박준선 ( Park Joon-Sun ) - Chungnam National University College of Pharmacy
이상민 ( Lee Sang-Min ) - Chungnam National University College of Pharmacy
 ( Kang Nae-Won ) - Seoul National University College of Pharmacy
 ( Lee Mee-Yeon ) - Seoul National University College of Pharmacy
조정원 ( Cho Cheong-Weon ) - Chungnam National University College of Pharmacy
김대덕 ( Kim Dae-Duk ) - Seoul National University College of Pharmacy
이재영 ( Lee Jae-Young ) - Chungnam National University College of Pharmacy

Abstract


Background: Chondrosarcoma (CHS) is the second most common sarcoma. However, pathogenesis and etiology of this malignant tumor are still unclear. The primary treatment method for CHS is surgery, and CHS is often resistant to conventional chemotherapy. There are various types of nanoscale therapeutics, such as liposomes, micelles, polymeric nanoparticles, and protein-based nanotherapeutics, which have shown promising results in the treatment of CHSs that are not capable of being surgically removed.

Area covered: The genetics and molecular targets of CHS and its diagnostic features observed by various modalities are introduced. Diverse types of nanoscale therapeutics and their clinical benefits in the treatment of cancer are also described. In addition, the current application of nanotechnologies to CHS treatment is discussed with various nanoplatforms designed for CHS.

Expert opinion: Nanotechnology-based approaches have been investigated to overcome the chemo-resistance of CHS. In particular, for CHS patients with no surgical treatment options, nanomedicine is one of the promising strategies for cancer treatment, along with the immunotherapy that is being spotlighted nowadays. We speculate that the combination of nano- and immuno-therapeutics would be a breakthrough in unresectable CHS treatment, as can be seen in the case of nivolumab plus nanoparticle albumin-bound rapamycin that has shown excellent clinical outcomes.

키워드

Chondrosarcoma; Molecular target; Diagnosis; Nanotechnology; Nanoscale therapeutics

원문 및 링크아웃 정보

등재저널 정보